Innoviva, Inc. — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
INVA
Innoviva, Inc. · Biotechnology
FCF$182mC
Rev+14.7%B+
D/E0.25B
P/E3.6xA
PEG0.33A
66.3Score
$22.20$1.6B
1Y Target$35.50Analyst consensus · 4 analysts
5Y Target$44.82Compound horizon
10Y Target$57.48Long-dated conviction
FCF$182mTTMC
FCF $182m — modest; watch for margin expansion
Rev+14.7%FY YoYB+
Revenue +14.7% — above sector median, healthy trajectory · Computed from last two annual revenue figures (FY YoY).
D/E0.25B
D/E 0.25 — near the Healthcare debt median (≈60th pctile)
P/E3.6xA
P/E 3.6 — cheapest decile in Healthcare (≈10th pctile)
PEG0.33A
PEG 0.33 — exceptional; paying well under fair value for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 66.3
Quality0.64
Growth0.48
Value0.94
Why this score
Diluting shareholders
Short track record
Entry · Margin of safety
52-week rangeMid-range
12% off the 12-month high
vs DCF fair value54% belowest. fair value ~$48
Quality signals · context only
ROIC7.9% · C+return on invested capital — not score-weighted
Why now
Biotechnology · market cap $1.6b. 12% off the 52-week high of $25.15. Revenue growing +15%, comfortably above the S&P median. PEG 0.33 — paying under fair value for the growth rate. 4 sell-side analysts publish a mean 1-yr target of $35.50 (implying +60% upside).
Moat
ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $35.50 (4-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $44.82 at ~15% CAGR — dividend + buyback compounding. 10 yr $57.48 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · INVA
$
%
%
Shares to buy
90
Position size
$1,998
4.0% of portfolio
Stop price
$16.65
25% below $22.20
$ at risk if stopped
$499.50
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Innoviva, Inc. (INVA): score, valuation & FAQ
Innoviva, Inc. (INVA) is a Biotechnology company that scores 66.3 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A), PEG (A) and Rev (B+). On valuation, INVA sits about 54% below our discounted-cash-flow fair value (a margin of safety).
Is INVA a good stock to buy?
Bull Rankings scores INVA 66.3 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A), PEG (A) and Rev (B+). A score is a quantitative screen of Innoviva, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does INVA score 66.3 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). INVA earns its highest marks on P/E (A), PEG (A) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is INVA overvalued or undervalued?
Based on $22.20, INVA sits about 54% below our discounted-cash-flow fair value (a margin of safety). It trades at a 3.6x× P/E (graded A). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in INVA?
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.